Diabetes Type 2

DELIVER-G: Real-world analysis in insulin-naïve adults with T2DM on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†1

RESTORE-G: Real-world analysis in insulin-naïve adults with T2D on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†2

Real-world safety and effectiveness of insulin glargine 300 U/mL in participants with type 2 diabetes who fast during Ramadan.

Summary of Zoungas S, et al. Diabetologia. 2012;55:636–643.

Practical Guidance based on the 2022 ADA/EASD Guidelines.

(Based on the study: Stratton IM, et al. BMJ. 2000;321(7258):405-12).

Summary of The UK Prospective Diabetes Study (UKPDS).